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Background: N-Acetyl-Cysteine (NAC), a natural sulfur-containing amino acid derivative, and peroxisome
proliferators activated receptor alpha (PPARα) ligand have been shown to have anticancer properties. However, the
mechanisms by which these agents inhibit human non-small cell lung carcinoma (NSCLC) cell growth have not
been well elucidated.
Methods: Small interfering RNAs (siRNAs) were used to knockdown 3-phosphoinositide-dependent protein kinase 1
(PDK1), PPARα, p65 and p53 genes; Western Blot was performed to detect the protein expression of PDK1, PPARα,
p65 and p53; Cell viability and MTT assays were carried out to determine the cell proliferation; Transient transfection
and Dual-Luciferase Reporter assays were used to transfect siRNAs or exogenous expression vectors, and to
measure the gene promoter activity.
Results: We showed that NAC inhibited NSCLC cell proliferation through reduction of PDK1 expression. NAC also
induced the protein expression of PPARα. While PPARα ligand enhanced, PPARα antagonist and siRNA abrogated
the effect of NAC on PDK1 promoter activity, protein expression and cell growth. Overexpression of PDK1
diminished the inhibitory effect of NAC on cell proliferation. NAC induced p53 and reduced p65 protein expression
through activation of PPARα. Silencing of p53 and overexpression of p65 blocked the effect of NAC on PDK1
promoter activity and protein expression.
Conclusion: Our results show that NAC inhibits PDK1 expression through PPARα-mediated induction of p53 and
inhibition of p65 protein expression. PPARα ligand enhances the effect of NAC. This ultimately inhibits NSCLC cell
growth. This study unveils a novel mechanism by which NAC in combination with PPARα ligand inhibits growth of
human lung carcinoma cells.
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Lung cancer continues to be the most frequent cancer-
related cause of death throughout the world with a poor
5-year survival rate (< 15%) [1]. New approaches to the
treatment and prevention of lung carcinoma depend on a
better understanding of the cellular and molecular
mechanisms that control tumor growth in the lung.
N-Acetyl-Cysteine (NAC), a natural sulfur-containing
amino acid derivative and a powerful antioxidant, has
been shown to inhibit inflammatory responses, tumor
progression [2,3]. However, the mechanisms by which
NAC inhibits growth of human lung cancer cells have
not been well characterized.
In an effort to explore the anti-tumor effects of
NAC on potential targets, we turned our attention to
3-phosphoinositide-dependent protein kinase 1 (PDK1), a
master regulator of signal cascades that are involved in
suppression of apoptosis and promotion of tumor growth
including lung cancer [4]. High expression of PDK1 has
been detected in various invasive cancers [5]. Reduction of
PDK1 by small interfering RNA (siRNA) in several cancer
cells results in significant cell growth inhibition [6]. These
observations suggest that PDK1 can be used as a potential
target for cancer therapies.
Peroxisome proliferators activated receptor alpha
(PPARα), a ligand-inducible nuclear transcription factor
that has been implicated in the pathogenesis and treatment
of tumor including lung cancer [7]. However, the exact role
that PPARα signaling plays involved in non small cell lung
carcinoma (NSCLC) biology and the mechanisms by which
PPARα ligands suppress tumor cell growth have not been
fully elucidated. A report showed that NAC could increase
PPARα activity [8].
Herein, our results show that NAC inhibits expression
of PDK1 expression through PPARα-mediated induction
of p53 and inhibition of p65 protein expression.
Methods
Culture and chemicals
NSCLC cell lines H1650, A549, H1792, H2106, H460
and H358 were obtained from the American Type
Culture Collection (Manassas, VA, USA), and were grown
in RPMI-1640 medium supplemented with 10% FBS,
HEPES buffer, 50 IU/mL penicillin/streptomycin, and 1 μg
amphotericin. All cell lines have been tested and authenti-
cated for absence ofMycoplasma, genotypes, drug response,
and morphology in the Laboratory in May 2010 and April
2012. Polyclonal antibodies specific for PDK1, PPARα, p65,
p50 and p53 were purchased from Cell Signaling Inc
(Beverly, MA, USA). The Dual-Luciferase Reporter
Assay kit was obtained from Promega (Shanghai, China).
N-Acetyl-Cysteine (NAC), GW6471, fenofibrate and all
other chemicals were purchased from Sigma Chemicals,
Inc. (St. Louis, MO, USA) unless otherwise indicated.Treatment with PDK1, PPARα, p65 and p53 small
interfering RNAs (siRNAs)
The siRNA human PDPK1 (EHU071261) was ordered
from Sigma, PPARα siRNA (sc-36307), and p65 siRNA
(sc-29410) were purchased from Santa Cruz Biotechnology.
Signal Silence p53 siRNA (#6231) was ordered from Cell
signaling. The control nonspecific siRNA oligonucleotide
(D-001206-13-05) was purchased from Dharmacon, Inc.
(Lafayette, CO, USA). For the transfection procedure, cells
were grown to 60% confluence, and PDK1, PPARα and p53
siRNAs and control siRNA were transfected using the
oligofectamine reagent (Invitrogen). Briefly, oligofectamine
reagent was incubated with serum–free medium for
15 min. Subsequently, a mixture of respective siRNA was
added. After incubation for 30 min at room temperature,
the mixture was diluted with medium and added to
each well. The final concentration of siRNAs in each
well was 70–100 nM. After culturing for 30 h, cells
were washed, resuspended in new culture media in
the control or treated plates for an additional 24 or 48 h
for the following experiments.
Western blot analysis
Equal amounts of protein from whole cell lysates
were solubilized in 2 × SDS-sample buffer, separated
on SDS-polyacrylamide gels. The separated proteins
were transferred onto nitrocellulose using a Bio-Rad
Trans Blot semidry transfer apparatus for 1 h at 25
voltages, blocked with Blotto with 5% nonfat dry milk
and 0.1% Tween 20 for overnight at 4 C, and washed with
wash buffer. Blots were incubated with polyclonal anti-
bodies against PDK1, PPARα, p53, p65 and p50 (1:1000)
for overnight at 37 C, washed and incubated with a sec-
ondary antibody raised against rabbit IgG conjugated to
horseradish peroxidase (1:15000, Sigma, Beijing, China)
for 1 h at room temperature. The washed blots were
transferred to freshly made ECL Prime (Pierce, Rockford,
IL, USA) and exposed to X-ray film.
Cell viability assay
NSCLC cells (105 cells/well) were transfected with
control, PDK1 or PPARα siRNAs for 30 h before exposing
the cells to NAC for an additional 48 h in 96-well plates.
In parallel experiments, cells were transfected with control
or overexpression PDK1 vector obtained from Addgene
[9]. Afterwards, the numbers of viable cells in culture were
determined using The CellTiter-Glo Luminescent Cell
Viability kit according to the manufacturer’s instructions
(Promega, USA).
MTT assay
Cell viability was analyzed by the MTT [3-(4, 5-
dimethylthiazol-2-yl)-2, 5-diphenyl tetrazolium bromide]
assay. Briefly, cells were seeded in 96-well plates at the
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for up to 48 h, and then 10 μL of 10 mg/mL MTT solution
was added to each well for an additional 4 h according to
manufacturer instructions. (Promega, Shanghai, China).
After centrifugation, 150 μL dimethyl sulfoxide was added
to the precipitate and the absorbance of the enzyme was
measured at 490 nm using an Microplate Reader (Bio-Rad,
Hercules, CA, USA). Cell growth rates (average absorbance
of each treated group and treated group) were then
calculated. All experiments were performed in triplicate
samples and repeated at least three times.
Transient transfection assay
The original human PDK1 promoter construct was a gift
from Dr. Michalik at the University of Lausanne and
have been reported previously [10]. The PDK1 promoter
construct contains approximately 1500 base pairs of the
5’ flanking region of the human PDK1 gene connected to
the pGL2 basic luciferase reporter vector [10]. Briefly,
NSCLC cells were seeded at a density of 5 × 105 cells/well
in 6-well dishes and grown to 50 –60% confluence. For
each well, 2 μg of the above PDK1 plasmid DNA con-
structs, or overexpression of PDK1(pDONR223-PDPK1)
[9], or p65 vectors (pCMV4 p65) [11] with 0.2 μg of the
internal control phRL-TK Renilla Luciferase Reporter
Vector were co-transfected into the cells with the
oligofectamine reagent (Invitrogen). In separate experi-
ments, cells were transfected with control or PDK1, PPARα
and p53 siRNAs (70 nM each) for 32 h followed by exposed
the cells to NAC for an additional 24 h. The preparation of
cell extracts and measurement of luciferase activities
were carried out using the Dual-Luciferase Reporter
Kit according to recommendations by the manufacturer.
Changes in firefly luciferase activity were calculated
and plotted after normalization with changes in Renilla
luciferase activity within the same sample.
Statistical analysis
All experiments were repeated a minimum of three times.
All data were expressed in mean ± SD. The data presented
in some figures are from a representative experiment,
which was qualitatively similar in the replicate experiments.
Statistical significance was determined with Student’s t test
(two-tailed) comparison between two groups of data
set. Asterisks shown in the figures indicate significant
differences of experimental groups in comparison with
the corresponding control condition (P < 0.05).
Results
NAC inhibits NSCLC cell proliferation through reduction
of PDK1 protein expression
We first examined the effect of NAC on growth of lung
carcinoma cells. A549 NSCLC cells exposed to increased
concentrations of NAC for up to 48 h showed a significantdecrease in cell proliferation with maximal reduction at
5 mM as determined by Luminescent Cell Viability Assay
(Figure 1A). Similar results were observed in other
NSCLC cell lines by this (Figure 1B) and as determined by
MTTassays (Figure 1C).
We next determined the effect of NAC on PDK1
protein expression. Cells exposed to NAC resulted in
significant decrease in PDK1 protein expression in a
dose- and time-dependent manner with maximal
induction noted at 5 mM at 24 h as determined by
Western Blot (Figure 1D-E). NAC also reduced PDK1
protein expression in other NSCLC cell lines (Figure 1F).
Overexpression of PDK1 has been reported to correlate
with tumor progression [5]. We found that overexpression
of PDK1 abrogated the effect of NAC on cell growth
(Figure 1G, lower panel). Transfection with PDK1
expression vector was confirmed by Western blot
(Figure 1G, upper panel). Together, these results sug-
gest that NAC inhibits NSCLC cell growth through
inhibition of PDK1.NAC induces protein expression of PPARα; blockade of
PPARα abrogates the inhibitory effect of NAC on PDK1
protein expression and cell growth
We next determined the effect of NAC on PPARα
protein levels. As shown in Figure 2A-B, NAC
induced PPARα protein expression in a dose- and
time-dependent manner with a maximal induction
observed at 5 mM for 24 h. Similar results were also
found in other NSCLC cell lines (Figure 2C). As we
expected, blockade of PPARα with a chemical inhibi-
tor, GW6471 [12], or the use of PPARα specific
siRNA [12] abrogated the inhibitory effect of NAC on
PDK1 protein expression (Figure 2D-E). Interestingly,
the agonists of PPARα, fenofibrate, reduced PDK1
protein expression (Figure 2D). Finally, PPARα antag-
onist significantly overcame, while PPARα agonist en-
hanced the inhibitory effect of NAC on cell
proliferation (Figure 2F).NAC reduces PDK1 promoter activity via PPARα
We also examined whether the effects of NAC on PDK1
expression occurred at the transcriptional level. As
shown in Figure 3A, the PDK1 promoter contains
multiple transcription factor binding sites including
c-myc, nuclear factor-κB (NF-κB), p53, among others.
We found that NSCLC cells transfected with wild-type
PDK1 promoter-luciferase reporter construct showed
decreased activity when exposed to NAC and fenofibrate
(Figure 3B). GW7461 blocked the inhibitory effect of
NAC and fenofibrate on PDK1 promoter activity
suggesting a PPARα-dependent signaling in this process
(Figure 3C).
Figure 1 NAC inhibits NSCLC cell proliferation through reduction of PDK1 protein expression. A-B, A549 NSCLC cells exposed to
increased concentrations of NAC for up to 48 h (A), or NSCLC cell lines indicated were treated with NAC (5 mM) for up to 48 h (B). Afterwards,
cell proliferation was determined by Luminescent Cell Viability Assay. C, NSCLC cell lines indicated were treated with NAC (5 mM) for up to 48 h.
Afterwards, cell proliferation was determined by MTT assays. Data are means ± SD from 3 separate experiments. * p < 0.01, compared with
untreated cells (CTR). D-E, Cellular protein was isolated from A549 cells that were cultured with increased concentrations of NAC as indicated for
24 h (D) or cultured with NAC (5 mM) for the indicated time period (E) followed by Western blot analysis with antibodies against PDK1 protein.
The bar graphs represent the mean ± SD of PDK1/GAPDH of at least three independent experiments. *indicates significant difference from
untreated control (0). F-G, Several NSCLC cells as indicated were treated with NAC (5 mM) for 24 h followed by Western blot for detecting PDK1
protein. (F) or A549 cells were transfected with control or overexpression of PDK1 vectors for 24 h, followed by exposure of the cells to NAC for
an additional 24 h. Afterwards, the luminescence of viable cells was detected using Cell Titer-Glo Luminescent Cell Viability Assay Kit. The upper
panels represent protein levels of PDK1 by Western blot (G). All data were depicted as mean ± SD. *indicates significant difference as compared
to the untreated control cells (CTR).
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through activation of PPARα; silencing of p53 and
overexpression of p65 diminish the effect of NAC on
PDK1 protein expression
In addition, we found that NAC increased protein
expression of p53, a tumor suppressor (Figure 4A), while
reducing NF-κB subunit, p65 protein expression in adose-dependent manner (Figure 4B). Note that NAC
had no effect on p50 protein (Figure 4B). Interestingly,
GW7461 blocked the effect of NAC on p53 and p63
protein expression (Figure 4C). Furthermore, silencing
of p53 or overexpression of p65 abrogated the effects of
NAC on PDK1 promoter activity (Figure 5A-B) and
protein expression (Figure 5C-D).
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Figure 2 (See legend on next page.)
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Figure 2 NAC induces protein expression of PPARα; Blockade of PPARα abrogates the inhibitory effect of NAC on PDK1 expression
and cell growth. A-B, Cellular protein was isolated from A549 cells that were cultured with increased concentrations of NAC for 24 h (A) or
cultured with NAC (5 mM) for the indicated time (B), followed by Western blot analysis with antibodies against PPARα. The bar graphs represent
the mean ± SD of PPARα/GAPDH of three independent experiments. *indicates significant difference from untreated control. C, Cellular protein
was isolated from NSCLC cell lines that were cultured with NAC for 24 h followed by Western blot analysis with antibodies against PPARα
protein. GAPDH used as loading control. CTR, indicates untreated cells. D, A549 cells were treated with GW6470 (20 μM) for 2 h before exposure
of the cells to NAC (5 mM), Fenofibrate (10 μM) for an additional 24 h. Afterwards, Western blot analysis was performed to detect PDK1 protein.
E, Cellular protein was isolated from A549 cells transfected with control or PPARα siRNA (100 nM each) for 30 h before exposure of the cells to
NAC (5 mM) for an additional 24 h. Afterwards, Western blot analysis was performed to measure PPARα and PDK1 proteins. The bar graphs
represent the mean ± SD of PDK1/GAPDH of three independent experiments. *indicates significant difference from untreated control. **indicates
significance of combination treatment as compared with NAC alone (P < 0.05). F, A549 and H1650 cells were treated with GW6470 (20 μM) for 2
h before exposure of the cells to NAC (5 mM), Fenofibrate (10 μM) for an additional 48 h. Afterwards, the luminescence of viable cells was
detected using Cell Viability Assay Kit. All data were depicted as mean ± SD. *indicates significant difference as compared to the untreated
group (CTR).
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NAC, a common dietary supplement and an antioxidant
membrane-permeable metal-binding compound, has been
shown to inhibit inflammatory responses, tumor growth in-
cluding lung cancer [13,14]. However, the mechanisms byA
B C
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Figure 3 NAC induces PDK1 promoter activity via PPARα. A, The hum
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Figure 4 NAC induces p53 and reduces p63 protein expression through activation of PPARα. A-B, Cellular protein was isolated from A549
cells cultured with NAC (5 mM) for 24 h, followed by Western blot analysis with antibodies against p53, p50 and p65 proteins. C, A549 cells were
treated with GW6470 (20 μM) for 2 h before exposure of the cells to NAC (5 mM) for an additional 24 h. Afterwards, Western blot analysis was
performed using polyclonal antibodies against p53 and p65 protein. The bar graphs represent the mean ± SD of p53 or p65/GAPDH of at least
three independent experiments. *indicates significance as compared with controls (CTR). **indicates significance of combination treatment as
compared with NAC alone (p < 0.05).
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[4,15]. High expression of PDK1 has been detected in
invasive cancers including lung [5] and inhibition of
PDK1 in several cancer cells results in significant cell
growth inhibition [6]. These observations suggest that
PDK1 can be considered as a target for therapies.
This result, together with the finding that exogenous
PDK1 diminishes the inhibitory effect of NAC on cell
growth, indicates an important role of targeting PDK1
in mediating the inhibitory effect of NAC on growth
of NSCLC cells.
PPARα, a ligand-inducible nuclear transcription factor
that has been implicated in the pathogenesis and treat-
ment of tumor including lung cancer both in vitro and
in vivo [7,16,17]. The exact role that PPARα signaling
plays in NSCLC and the mechanisms by which PPARα
ligands suppress tumor cell growth have not been fully
elucidated. A report showed that NAC could increase
PPARα activity [8]. Because of this, we will further testthe role of PPARα and the effect of PPARα ligands
on PDK1 expression. Our results showed that NAC
increased protein expression of PPARα and the synergism
of NAC and PPARα ligands on cell growth inhibition
demonstrated an important role of this nuclear transcrip-
tion factor in mediating the inhibitory effect of NAC on
PDK1 expression and on NSCLC cell proliferation. Our
result suggested that PPARα agonist could sensitize the
effect of NAC on cell growth inhibition and also implied
that NAC may act as a potential PPARα ligand. Consistent
with this, one report demonstrated a synergistic effect
of PPARα agonist and NAC in control of brain tumor
cells [18].
Note that no report showed a link between PPARα
ligand and PDK1 although PDK1 was reported to be
a target gene of PPARσ/β [19], another isoforms of
PPAR family, which strongly expressed in the majority
of lung cancers, and activation of this isoform induced
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Figure 5 Silencing of p53 and overexpression of p65 diminish the effect of NAC on PDK1 promoter activity and protein expression.
A-B, A549 cells (1 × 105 cells) were cotransfected with a wild type PDK1 promoter construct and an internal control phRL-TK Renilla Luciferase
Reporter Vector, and control or p53 siRNA (100 nM) for 40 h (A) or co-transfected with control or pCMV6 p65 expression vector (B) for 24 h,
followed by NAC for an additional 24 h. Afterwards, luciferase assays were performed to detect PDK1 promoter activity. C-D, A549 cells were
transfected with control or p53 siRNA (100 nM) for 40 h (C), and control or p65 overexpression vector for 24 h (D), followed by NAC for an
additional 24 h. Afterwards, Western blot was performed to detect p53, p65 and PDK1 proteins. The bar graphs represent the mean ± SD of
PDK1/GAPDH of at least three independent experiments. *indicates significance as compared with controls (CTR). **indicates significance of
combination treatment as compared with NAC alone (p < 0.05).
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regulation of PDK1 [20]. Note that the PDK1 promoter
contains peroxisome proliferator responsive element
(PPRE) [19], our data showed that PPARα ligand inhibited
PDK1 promoter activity suggesting a distinct function of
PPARα activation as compared to that of PPARσ/β. More
studies are required to elucidate this.
Furthermore, our results indicated that NAC–mediated
downregulation of PDK1 reflected inhibition of transacti-
vation of the PDK1 gene and also demonstrated thatNAC, through activation of PPARα, increased tumor
suppressor, p53 and reduced p65, a subunit of NF-κB,
which played important roles in mediating the effect
of NAC on inhibition of PDK1 expression. This again
suggested the characteristic of NAC acted as PPARα
ligand. Silencing of p53 and overexprerssion of p65
blocked the effects of NAC on PDK1 expression further
confirm the key roles of p53 and p65 in this process.
P53 plays a critical role in tumor suppression mainly
by inducing growth arrest, blocking angiogenesis and
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[21]. Transcription factor NF-κB has been shown to regu-
late the expression of a number of genes that involve in
many cellular processes such as inflammation and tumor
growth [22]. Interestingly, the link of p53 in the regulation
of glycolysis-dependent activation of NF-κB signaling in
cancer has been reported [23]. However, the role of p53
and NF-κB in the direct regulation of PDK1 expression
remains unknown. On the contrary, one study showed
that overexpression of PDK1 resisted the apoptotic
cell death caused by hypoxic injury and increased the
expression of survival proteins, such as p53, in cultured rat
cardiomyocytes [24]. Also, reports found that PDK1 plays
a critical role by nucleating the T cell receptor-induced
NF-κB activation pathway, which is important for T cell
proliferation and activation during the adaptive immune
response [25]. Together, these findings indicated that
PDK1 was a critical regulator of tumor cell survival by
modulating the p53 and NF-κB signaling pathways. NAC
also had a direct or indirect effect on the regulation of p53
and NF-κB [26,27]. The activation of p53 has been shown
to mediate the effects of NAC on prostate cancer cell
growth [28]. One study reported that NAC inhibited
growth of liver cancer cells through reducing the
expression of NF-κB subunit p65 suggesting that
NAC may be used for the treatment of liver tumor
[29]. Thus, knockdown of p53 and overexpression of
p65 abrogated the effect of NAC on PDK1 expression
and cell proliferation highlighted the critical role of p53
and p65 in this process.Conclusion
In summary, our results show that NAC inhibits
PDK1 expression through PPARα-mediated induction
of p53 and reduction of p65 protein expression.
Activation of PPARα enhances this process. This
leads to inhibit NSCLC cell growth. This study unveils a
novel mechanism by which NAC in combination
with PPARα ligand inhibits growth of human lung
carcinoma cells.
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